Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) shares declined 1.43 percent to close at $90.71 a share Wednesday. The stock traded between $89.56 and $92.89 on volume of 404,465 shares traded. Analysts at FBR Capital have recently initiated coverage on the company with an "outperform" rating. Shares of Jazz Pharmaceuticals have gained approximately 70.0 percent year-to-date.
Find out more about Jazz Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/JAZZ
Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) shares declined 13.94 percent to close at $60.01 a share Wednesday. The stock traded between $56.25 and $66.34 on volume of 10.40 million shares traded. Analysts at CRT Capital have recently downgraded the company’s rating to "fair value" from "buy". Shares of Questcor Pharmaceuticals have gained approximately 125.0 percent year-to-date.
Find out more about Questcor Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/QCOR
Rosetta Genomics Ltd. (NASDAQ: ROSG) shares declined 12.90 percent to close at $2.70 a share Wednesday. The stock traded between $2.50 and $3.01 on volume of 725,995 shares traded. Analysts at Aegis Capital have recently downgraded the company’s rating to "hold" from "buy". Shares of Rosetta Genomics have fallen approximately 42.0 percent year-to-date.
Find out more about Rosetta Genomics including full access to the free equity report at:
www.RDInvesting.com/ROSG
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares declined 5.70 percent to close at $71.75 a share Wednesday. The stock traded between $70.76 and $75.37 on volume of 2.69 million shares traded. Analysts at Summer Street Research have recently downgraded the company’s rating to "neutral" from "buy". Shares of Vertex Pharmaceuticals have gained approximately 70.0 percent year-to-date.
Find out more about Vertex Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/VRTX
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
info@rdinvesting.com